Brexit Effect on Biosimilars

The Brexit effect on Biosimilars tends to be negative. Not only would it be a major setback towards approval and launch of biosimilars to the market but also it would be hindrance towards the cost cutting approach taken up by NHS.With Britain being among principal clinical trial centers is owned to see a decrease in the willingness of the manufacturers and researchers to carry out any further trials in Britain. Also Brexit will cause the principal motive of Bristish Biosimilars Association(BBA) to fall back- which aimed at increasing the use of biosimilars.

    Related Conference of Brexit Effect on Biosimilars

    October 16-18, 2017

    12th World Pharma Congress

    Budapest, Hungary
    October 16-18, 2017

    11th World Drug Delivery Summit

    (10 Plenary Forums - 1Event)
    Baltimore, Maryland, USA
    October 16-17, 2017

    10th International Conference and Exhibition on Biologics and Biosimilars

    San Francisco, California, USA
    November 09-11, 2017

    4th European Biopharma Congress

    Vienna, Austria
    August 20-22, 2018

    9th Asian Biologics and Biosimilars Congress

    Tokyo, Japan

    Brexit Effect on Biosimilars Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in